USPTO serial 88072409
NANOGENICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 14, 2020
- Examiner
- COLLOPY, DIANE PATRICIA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NANOGENICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $850
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas W. Cole
Thomas W. Cole ROBERTS MLOTKOWSKI SAFRAN COLE & CALDERON P.C.7918 JONES BRANCH DRIVE, SUITE 500MCLEAN, VA 22102UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing siRNA, RNA, shRNA, mRNA or DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; pharmaceutical medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing siRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing shRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing mRNA for treatments in the form of gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in gene therapy for the treatment of tumours; biochemical preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations being nanoparticles for the treatment of cancer; pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals ; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations in the form of nanoparticles; drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; none of the aforesaid for use in relation to the treatment of hair loss or hair growth stimulation | ACTIVE | — |
| 042 | Medical and pharmacological research services all in the field of gene therapy and treatment of cancer; biological research, clinical research and medical research all in the field of gene therapy; research in the field of gene therapy; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical product development; research of pharmaceuticals; research relating to pharmaceutical delivery agents; development of pharmaceutical delivery agents; research and development in the pharmaceutical and biotechnology fields; providing information about the results of clinical trials for pharmaceutical products; scientific research services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and substances; development of pharmaceuticals and pharmaceutical preparations being nanoparticles; development of pharmaceuticals and pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA; development of drug delivery agents being made from lipids, liposomes or peptides; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations; development of pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material; development of pharmaceuticals and pharmaceutical preparations for use in gene therapy; development of drug delivery agents for use in gene therapy; development of drug delivery agents being nanoparticles; providing consulting to medical research companies in the design and conduct of clinical trials and proving consulting to pharmaceutical companies in the design of pharmaceutical products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nanogenics Limited
- Other trademarks owned by Nanogenics Limited
- Other trademarks owned by Nanogenics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named NANOGENICS
- Prosecution event R.PR explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 14, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 10, 2020 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Jun 8, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 29, 2020 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 29, 2020 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Apr 28, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 28, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 21, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 25, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 25, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 21, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 28, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 27, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 27, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 30, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 30, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 30, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 3, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 30, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 27, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 25, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 25, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 25, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 17, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 13, 2018 | NWAP | NEW APPLICATION ENTERED | — |